Pancreatic, colorectal, and liver cancers are notoriously quiet killers because they rarely show symptoms in their early stages, and non-invasive detection tools have historically been lacking. To solve this clinical hurdle, the EG BioMed research team—in close collaboration with Taipei Medical University and its hospital network (TMUH, Wanfang, Shuang Ho)—has developed a high-performance liquid biopsy…

On April 25, 2026, EG BioMed proudly renewed its support as both a sponsor and an active participant in PurpleStride 2026, the nationwide walk organized by the Pancreatic Cancer Action Network (PanCAN). Walking alongside survivors, families, healthcare professionals, and researchers, our team stood united in a shared mission: to elevate public awareness of pancreatic cancer…

YD Bio Limited has entered into a Memorandum of Understanding (the “MOU”) to merge with EG BioMed, a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics. The proposed merger represents a strategic step in building an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery.…